Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)

Inclusion Criteria: * Diagnosis of AATD * Liver biopsy indicating Metavir F1-F3 liver fibrosis based on local pathology read. * Women of childbearing potential must have a negative pregnancy test, cannot be breast feeding, and must be willing to use contraception * Willing to provide written informed consent and to comply with study requirements * Non-smoker for at least 1 year * No abnormal finding of clinical relevance at screening Exclusion Criteria: * Clinically significant health concerns other than AATD * Previous diagnosis or diagnosis at Screening of definitive liver cirrhosis * Regular use of alcohol within one month prior to Screening * Use of an investigational agent or device within 30 days prior to dosing or current participation in an investigational study involving therapeutic intervention * Use of illicit drugs within 1 year prior to Screening Note: additional inclusion/exclusion criteria may apply, per protocol